Nuformix plc (NFX.L)

0.2050 -0.0025 (-1.20%) At close: 12:19PM BST

Nuformix plc

60 Gracechurch Street
6th Floor
London EC3V 0HR
United Kingdom
44 12 2362 7222
https://www.nuformix.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 3

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Daniel John Gooding	Executive Director	30k	N/A	1973
Dr. Joanne M. Holland	Consultant	66k	N/A	1975
Mr. Benjamin Harber	Company Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.

Corporate governance

Nuformix plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.